Can Systemic Sarcoidosis and Genetic Cardiomyopathy Coexist? Authors: Anjali A Wagle, Ria Gupta, Maham Karatela, Brittney Murray, Nisha A Gilotra, Paul J Scheel Published: 2026 ABSTRACT AbstractGenetic cardiomyopathies and cardiac sarcoidosis share overlapping features, complicating diagnosis when both conditions coexist. We describe 3 patients with filamin C–associated, plakophilin-2–associated, and MYBPC3-associated cardiomyopathies who were later diagnosed with extracardiac sarcoidosis. Despite imaging findings concerning cardiac sarcoidosis, only 1 patient demonstrated active myocardial inflammation warranting immunosuppression; the others were managed as primary genetic cardiomyopathy. These cases illustrate the limited specificity of cardiac imaging in patients with known genetic cardiomyopathy and highlight the need for careful, individualized assessment to determine whether sarcoid inflammation contributes to arrhythmias or ventricular dysfunction.Key words: arrhythmogenic cardiomyopathy, cardiac sarcoidosis, extracardiac sarcoidosis, FDG-PET imaging, FLNC variant, genetic cardiomyopathy, hypertrophic cardiomyopathy, PKP-2 variant Representative FDG-PET and Cardiac MRI Findings from 3 Patients With Biopsy-Proven ECS and Genetic Cardiomyopathies (Filamin C Mutation, Arrhythmogenic Right Ventricular Cardiomyopathy, and Hypertrophic Cardiomyopathy) Demonstrate How Structural and Functional Abnormalities Can Resemble Cardiac Sarcoidosis All cases show late gadolinium enhancement (LGE) but limited or absent FDG uptake except in one with active ECS, highlighting the diagnostic challenge and the need for careful integration of imaging with clinical and genetic data. ECS = extracardiac sarcoidosis; FDG-PET = fluorodeoxyglucose positron emission tomography; MRI = magnetic resonance imaging; Tx = treatment. Significant phenotypic overlap has been described between arrhythmogenic genetic cardiomyopathies and cardiac sarcoidosis (CS), with diagnostic evaluation ultimately confirming one of these diagnoses. However, the dual presence of sarcoidosis with genetic cardiomyopathy is less described and understood. Determining the etiology of cardiomyopathy in patients with extracardiac sarcoidosis (ECS) presents a diagnostic challenge. This case series presents 3 patients with genetic cardiomyopathy and coexisting ECS. We discuss the clinical presentations and review the key diagnostic challenges associated with differentiating cardiomyopathy in patients with suspected CS. Patient 1: Filamin C–Associated Cardiomyopathy A 59-year-old male was found to have frequent premature ventricular contractions on an electrocardiogram (ECG) during a routine annual primary care visit. The ECG showed a first-degree atrioventricular block. Transthoracic echocardiogram (TTE) demonstrated a left ventricular (LV) ejection fraction (EF) of 20%-25% and an LV diastolic diameter of 6.6 cm. The patient’s family history was significant for dilated cardiomyopathy with multiple sudden cardiac deaths. An ischemic evaluation was unremarkable. Genetic testing was recommended but not completed. His sister’s initial genetic testing panel was negative for pathogenic variants at that time. The patient was presumed to have familial cardiomyopathy and was initiated on guideline-directed medical therapy for heart failure. The patient continued to have a high burden of nonsustained ventricular tachycardia (VT). Given persistently reduced LV function and a family history of sudden cardiac death, a single-chamber implantable cardioverter-defibrillator (ICD) was inserted. One year later, he developed abrupt lightheadedness and dizziness with a work-up notable for no arrhythmias, but chest computed tomography (CT) angiography revealed bulky mediastinal adenopathy. A transbronchial biopsy of lung parenchyma showed noncaseating granulomas, and ultimately the patient was found to have pulmonary sarcoidosis. Given the diagnosis of biopsy-proven pulmonary sarcoidosis, frequent ventricular ectopy, and reduced LV EF, CS was considered a potential etiology for his dilated cardiomyopathy. He subsequently underwent endomyocardial biopsy (EMBx), which did not demonstrate granulomatous disease. Ten years later, he underwent cardiac magnetic resonance (CMR) imaging, which demonstrated EF recovery and patchy late gadolinium enhancement (LGE). Given his diagnosis of pulmonary sarcoidosis and the CMR findings, a cardiac fluorodeoxyglucose positron emission tomography (FDG-PET) scan was performed, revealing no FDG avidity. He underwent genetic testing because of the identification of a likely pathogenic variant that segregated with the cardiomyopathy and sudden death in his family: Filamin C (FLNC)–associated cardiomyopathy c.4737+5G>A. Expert Commentary The patient demonstrated a clinical phenotype, family history, and genetic testing results consistent with FLNC-associated cardiomayopathy. He was subsequently diagnosed with biopsy-proven pulmonary sarcoidosis, and based on the Heart Rhythm Society diagnostic criteria for CS, the patient met criteria for probable CS during the time that his family’s genetic testing was negative. Given dual diagnoses of FLNC-associated cardiomyopathy and sarcoidosis, this case highlights the complexity of assessing which disease was contributing toward his cardiac clinical phenotype and, therefore, whether he would benefit from sarcoidosis-specific treatment, namely immunosuppression. With regard to treatment, his ECS was quiescent and did not require initiation of immunosuppression. From a cardiac standpoint, he had frequent nonsustained VT and 1 episode of VT; however, his CMR and FDG-PET demonstrated no evidence of active inflammation, which favored FLNC-associated cardiomyopathy as the predominant etiology of the patient's arrhythmic cardiac phenotype. As such, although the CMR findings of inferoseptal and inferior mid-myocardial LGE were characteristic and possibly reflective of prior active CS, the absence of current inflammatory activity did not justify initiation of immunosuppression therapy. Patient 2: Arrhythmogenic Right Ventricular Cardiomyopathy A 16-year-old male patient first presented to the emergency department with monomorphic VT and underwent a VT ablation, and years later, he received an ICD. The ECG was notable for epsilon waves and precordial T-wave inversions. A TTE showed normal LV function with moderately decreased right ventricular (RV) function and moderate RV dilation. A CMR imaging scan showed a thin and akinetic RV free wall as well as delayed enhancement of the RV myocardial free wall, suggestive of fatty infiltration. There was minimal LGE of the LV. An EMBx showed moderate myocyte hypertrophy with mild to moderate interstitial fibrosis and rare adipose tissue, concerning for fibrofatty infiltration. He underwent genetic testing showing a pathogenic plakophilin-2 variant: c.148_151del (p.Thr50Serfs∗61) consistent with arrhythmogenic right ventricular cardiomyopathy (ARVC). He continued to require recurrent VT ablations because of sustained VT with ICD shocks despite maximal medical therapy. Eleven years after the initial presentation of VT, he developed decompensated heart failure, prompting an evaluation for heart transplantation. A screening CT scan revealed large retroperitoneal and iliac lymph nodes, prompting a whole-body FDG-PET scan, which showed cervical, mediastinal, abdominal, and pelvic FDG-avid lymphadenopathy. A supraclavicular lymph node biopsy showed non-necrotizing granulomas consistent with ECS. The FDG-PET scan and CMR imaging showed perfusion defects and LGE, respectively, in the inferior lateral apical walls and no evidence of active inflammation. Immunosuppression was deferred for sarcoidosis treatment. He underwent orthotopic heart transplantation, and surgical pathology of the native heart explant showed myocyte hypertrophy with patchy interstitial fibrosis consistent with ARVC and no evidence of CS. Expert Commentary The patient presented with ARVC complicated by recurrent VT and cardiogenic shock, requiring evaluation for a heart transplant. During this evaluation, he was incidentally found to have lymphadenopathy, which on biopsy was consistent with a histopathologic diagnosis of sarcoidosis. Subsequent cardiac imaging findings alongside his history of VT, in the right context, would qualify for a diagnosis of probable CS. Given the incidental nature of the sarcoidosis diagnosis and the substantial overlap in the diagnostic features between ARVC and CS, the diagnosis of CS remained uncertain. Additionally, it was noted that the patient was a former firefighter and was at an increased risk for developing granulomatous lung disease in the setting of inhalation injury, as an explanation for his lymph node findings.1 At this juncture, several critical clinical considerations arose, chief among them being whether a trial of immunosuppressive therapy should be initiated before heart transplantation. However, in the absence of active myocardial inflammation on an FDG-PET scan and a CMR imaging, the patient’s cardiomyopathy and recurrent VT were attributed predominantly to his gene-positive ARVC, and the decision was made to defer immunosuppressive treatment. Patient 3: Hypertrophic Cardiomyopathy A 39-year-old man with seronegative rheumatoid arthritis presented to the clinic after his father was diagnosed with hypertrophic cardiomyopathy (HCM). A TTE showed eccentric septal hypertrophy with a maximal wall thickness of 1.7 cm, no evidence of outflow tract obstruction, and an LV EF of 65% to 70%. A Holter monitor showed rare premature ventricular complexes. Genetic testing revealed a pathogenic MYBPC3 variant in the patient and his father (c.655G>C [p.Val219Leu]). The patient was diagnosed with HCM. Three years later, he developed a cough, with a chest CT scan showing mild mediastinal lymphadenopathy. Bronchoscopy with biopsy showed noncaseating granulomas consistent with pulmonary sarcoidosis. He also had clinical findings consistent with articular sarcoidosis and was initiated on prednisone. Given his HCM and new diagnosis of pulmonary sarcoidosis, he underwent a CMR while on prednisone, which did not show delayed enhancement. Seven years later, he developed palpitations and underwent a repeat CMR imaging that showed 10% LGE in the LV septum and inferoseptal RV insertion points, consistent with HCM. He was referred to electrophysiology, given his father’s history of ICD placement and his own LGE on CMR. He underwent an electrophysiology study and an atrial tachycardia ablation, which had no inducible sustained ventricular arrhythmias. One year later, he continued to have palpitations with lightheadedness, with a work-up revealing a 2:1 atrioventricular block and a subsequent syncopal event associated with bradycardia, at which an ICD was inserted. Given his history of pulmonary sarcoidosis, LGE on CMR, and a new conduction defect, he underwent an FDG-PET scan, which showed FDG uptake in the LV inferoseptal wall. He was started on immunosuppression for CS with prednisone and mycophenolate mofetil. Expert Commentary The patient had HCM diagnosed by genetics, family history, and cardiac morphology and was subsequently diagnosed with clinically active pulmonary sarcoidosis. Cardiac evaluation revealed FDG uptake and LGE concerning a diagnosis of probable CS. The diagnosis of CS remained uncertain as the imaging findings—though suggestive—had been reported in patients with HCM and lacked definitive clinical manifestations typically associated with CS, such as conduction system disease, VT, or unexplained cardiomyopathy.2 Therefore, despite the FDG uptake observed on FDG-PET imaging, a conservative approach involving close observation without immunosuppressive therapy could have been justified pending the development of overt cardiac involvement. However, the presence of active, symptomatic pulmonary and articular sarcoidosis necessitated the initiation of systemic immunosuppressive therapy. Discussion This case series is clinically important because it highlights the ambiguity and challenge of determining the presence of myocardial sarcoid involvement and the need for treatment in patients with known genetic cardiomyopathy. Prior reports focusing on overlap diseases have largely focused on ARVC and CS overlap.3,4 Current guidelines for the diagnosis of CS, as outlined by the Japanese Circulation Society and the Heart Rhythm Society, establish criteria for both definitive and probable diagnoses.5,6 According to these guidelines, a definitive diagnosis of CS can only be achieved through myocardial tissue biopsy demonstrating noncaseating granulomas. However, the sensitivity of EMBx is limited because of the patchy distribution of sarcoid granulomas within the myocardial tissue.7 This low sensitivity with the inherent procedural risks of EMBx renders it an infrequently utilized diagnostic tool for cardiac involvement of sarcoidosis in patients with established ECS. As a result, the diagnostic framework emphasizes clinical and imaging criteria to support a presumptive diagnosis (Figure 1).8 Clinical indicators include conduction abnormalities, sustained VT, and reduced LV EF, whereas imaging findings such as increased FDG uptake on an FDG-PET scan and LGE on CMR imaging provide further supportive evidence. Algorithm Illustrating Evaluation and Treatment Decisions When Genetic Cardiomyopathy Coexists With Systemic Sarcoidosis Management hinges on evidence of cardiac sarcoidosis (CS) and the safety of immunosuppression (IS). CMR = cardiac magnetic resonance; FDG-PET = fluorodeoxyglucose positron emission tomography. Notably, current diagnostic and treatment guidelines for CS have been developed primarily for patients without a pre-existing diagnosis of genetic cardiomyopathy. In individuals with established genetic cardiomyopathies, the evaluation for CS becomes significantly more nuanced because of the considerable overlap in the clinical presentation and diagnostic criteria. Phenotypically, many genetic cardiomyopathies—including ARVC, HCM, and other genetic arrhythmogenic cardiomyopathies, including FLNC and lamin A/C manifest with ventricular arrhythmias and heart failure, features that closely resemble those seen in CS. From an imaging standpoint, the specificity of FDG-PET in this population has been called into question as abnormal myocardial FDG uptake has been reported in several genetic cardiomyopathies.2,9,10 These findings suggest the possibility of inflammatory phases within certain genetic cardiomyopathies, which may mimic the imaging appearance of CS and complicate diagnostic and therapeutic decision-making. In patients with known genetic cardiomyopathies who are subsequently diagnosed with ECS, a key clinical consideration is whether active inflammation from CS is the underlying cause of ventricular arrhythmias, heart failure, or other manifestations of cardiac dysfunction. Given the significant overlap between genetic cardiomyopathies and CS in clinical presentation and imaging, and given the limited sensitivity of EMBx, determining the primary driver of each patient’s phenotype can be challenging. However, this distinction is essential as identifying CS as the primary driver would support the use of immunosuppressive therapy, which has the potential to reverse inflammation-mediated cardiac injury and improve clinical outcomes. In this case series, all 3 patients had established genetic cardiomyopathy and were subsequently diagnosed with biopsy-proven ECS. Among them, only one was determined to have an active CS warranting the initiation of immunosuppressive therapy, whereas the remaining 2 were managed primarily as genetic cardiomyopathies. Assessment for active myocardial inflammation relies heavily on advanced imaging techniques, including T2-weighted imaging on CMR and FDG uptake on a CS protocol FDG-PET scan. However, considering recent reports demonstrating FDG uptake in various genetic cardiomyopathies, these imaging findings must be interpreted with caution. It is essential to consider the broader clinical context, including the certainty of the ECS diagnosis and the presence of clinical indicators suggestive of active cardiac involvement, when determining whether to initiate immunosuppressive therapy. Additionally, potential contraindications to immunosuppressive therapy must be carefully considered, particularly the presence of malignancy or active or chronic infections, which may warrant deferring or modifying treatment (Figure 1). This case series adds to the existing literature in underscoring the diagnostic complexity and need for a more nuanced and individualized approach to evaluating for a dual diagnosis of CS in patients with genetic cardiomyopathy and ECS. This case series underscores the potential for diagnostic ambiguity, driven by overlapping clinical phenotypes and the inherent limitations of current noninvasive diagnostic modalities. Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose. Take-Home Messages •Genetic cardiomyopathies and cardiac sarcoidosis share overlapping clinical and imaging features, making etiologic attribution challenging when both conditions coexist. Genetic cardiomyopathies and cardiac sarcoidosis share overlapping clinical and imaging features, making etiologic attribution challenging when both conditions coexist. •In patients with known genetic cardiomyopathies, fluorodeoxyglucose positron emission tomography and cardiac magnetic resonance findings concerning for sarcoidosis require cautious interpretation as these abnormalities may also appear in genetic diseases. In patients with known genetic cardiomyopathies, fluorodeoxyglucose positron emission tomography and cardiac magnetic resonance findings concerning for sarcoidosis require cautious interpretation as these abnormalities may also appear in genetic diseases. •Determining whether sarcoid inflammation is contributing to arrhythmias or ventricular dysfunction is essential as only true, active cardiac sarcoidosis warrants immunosuppressive therapy. Determining whether sarcoid inflammation is contributing to arrhythmias or ventricular dysfunction is essential as only true, active cardiac sarcoidosis warrants immunosuppressive therapy. Footnotes The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the Author Center. References